A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Completed · Phase 1

Conditions studied: Parkinson's Disease (PD)

In brief

The purpose of the study is to assess the safety, tolerability, and pharmacokinetics of single, ascending doses of ABBV-951 administered as a subcutaneous bolus infusion followed by a continuous subcutaneous infusion in subjects with Parkinson's disease.

Key facts

Study ID

NCT03033498

Run by

AbbVie

People needed

29

Starts

2017-05-17

Expected to finish

2019-06-08

Last updated by the study team

2024-11-12

Who can join

Age: 45 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has a diagnosis of definite idiopathic PD, which is LD responsive, according to the United Kingdom Parkinson's Disease Society Brain Bank Criteria.
• Subject must be taking an optimized and stable regimen of oral medications for PD, which has remained stable and unchanged for at least 30 days before dosing in this study. This regimen must include oral carbidopa/levodopa (CD/LD) tablets (e.g., Sinemet).
• Females must have negative results for pregnancy tests at screening and prior to confinement.
• If male, subject must be surgically sterile or practicing an adequate method of birth control from initial study drug administration until 30 days after last dose of study drug.
• Body Mass Index (BMI) is 18.0 to 38.0, inclusive.
• A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).

You may not qualify if…

• Receipt of any drug by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration.
• History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis, etc.) or evidence of recent sunburn, acne, scar tissue, tattoo, open wound, branding, or colorations that in the Investigator's opinion would interfere with the infusion of the study drug or could interfere with study assessments.
• Use of any medication from the prohibited concomitant therapies.
• Subjects with glomerular filtration rate (GFR) less than 45 ml/min/1.73 m2 as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.
• Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to initial study drug administration.
• Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951.

Where it is running

• Glendale Adventist Medical Ctr /ID# 166512 — Glendale, California, United States
• Bioclinica Research - Orlando /ID# 169687 — Orlando, Florida, United States
• Acpru /Id# 154976 — Grayslake, Illinois, United States
• University of Kentucky Chandler Medical Center /ID# 169086 — Lexington, Kentucky, United States
• Parexel Baltimore /ID# 169255 — Baltimore, Maryland, United States
• QUEST Research Institute /ID# 166035 — Farmington Hills, Michigan, United States
• Carolina Phase I, LLC /ID# 166034 — Raleigh, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.